Logo of Curvebeam AI (ASX:CVB)Latest Curvebeam AI (ASX:CVB) News

Page 1
Page 1 of 4

CurveBeam AI lands first four-system China order after HiRise clearance

CurveBeam AI has received its first Chinese order for four HiRise weight-bearing CT systems from Weiying/Wego Orthopedics, turning regulatory clearance into an initial commercial foothold. The order value and delivery schedule were not disclosed, while a further A$1 million milestone investment is expected this quarter.
Victor Sage
19 Nov 2026

Healthcare Wrap - Week 43 (19 Oct -> 23 Oct) 2026

Healthcare shares ended a difficult week with funding worries weighing on smaller companies, even as several groups reported stronger sales or clinical progress. Starpharma, Hydration Pharmaceuticals and Saluda were among the largest fallers, while Recce, Zoono and Genetic Signatures posted gains.
Logan Eniac
24 Oct 2026

CurveBeam AI clears China hurdle as HiRise orders hit quarterly record

CurveBeam AI has secured its strongest first-quarter HiRise sales result, gained China regulatory clearance and raised A$7.35 million to fund the next stage of commercialisation. The progress comes alongside lower customer receipts and a reported 4.3 quarters of cash runway.
Victor Sage
21 Oct 2026

Market Wrap - Week 38 (14 Sept -> 18 Sept) 2026

Small-cap resources led the week, while takeover offers and defence contracts added support across the market.
Investors still had to weigh approvals, cash needs and project delivery against strong headline results.
Logan Eniac
19 Sept 2026

CurveBeam AI raises A$1.75m as China expansion funding gathers momentum

CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.
Victor Sage
18 Sept 2026

CurveBeam AI Secures FDA Clearance for CT-Based Bone Density Technology

CurveBeam AI has secured FDA 510(k) clearance for CT-based bone mineral density measurement, establishing the first regulatory step towards a potential new SaaS offering. The more commercially significant HiRise weight-bearing application still requires a separate clearance.
Victor Sage
15 Sept 2026

Market Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Small-cap shares produced another uneven week, led by a major fall in Corporate Travel Management and strong gains in energy, gas and takeover stocks.
Investors rewarded rising profits and new deals, but sold several companies despite promising project news.
Logan Eniac
5 Sept 2026

Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026

Healthcare shares delivered a mixed week as commercial wins and trial progress competed with fresh losses and capital needs.
Large moves in Alzheimer’s, fertility, diagnostics and medical devices gave investors clear milestones to track.
Logan Eniac
5 Sept 2026

CurveBeam AI Raises A$606K via Share Purchase Plan to Support HiRise China Launch

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.
Ada Torres
1 Sept 2026

CurveBeam AI Reports FY2026 Revenue Drop Amid China Expansion and Capital Raise

CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.
Ada Torres
31 Aug 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

CurveBeam AI Receives A$2.4 Million in Partial Placement, Issues 120 Million Shares

CurveBeam AI has secured nearly half of its A$5 million placement at $0.02 per share, issuing 120 million shares to key investors while awaiting the remainder of funds from Intellivision Holdings.
Ada Torres
28 Aug 2026